# BPC-157 5mg + TB-500 5mg (blend) dosage & reconstitution (10 mg vial)

BPC-157 5mg + TB-500 5mg (blend) dosage: calculations for a 10 mg vial use the same amounts described in the literature. Adding 2 mL of bacteriostatic water produces 5 mg/mL, so each U-100 unit contains 50 mcg.

- **Vial contents:** 10 mg BPC-157 5mg + TB-500 5mg (blend)
- **Final volume:** 2 mL
- **Concentration:** 5 mg/mL
- **One U-100 unit:** 50 mcg in 0.01 mL

## Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing

### Standard / Gradual Approach (2 mL = ~5 mg/mL)

| Week / phase | Daily dose | Each peptide | Units per injection (mL) |
|---|---|---|---|
| Weeks 1–2 (Initial) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 12 units (0.12 mL) |
| Weeks 3–4 (Loading) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 16 units (0.16 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 12 units (0.12 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

### Reconstitution Steps

1. Draw 2 mL of bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid shaking to prevent foaming.
3. Gently swirl or roll until fully dissolved (clear solution).
4. Label with the reconstitution date and refrigerate at 2–8 °C, protected from light; use within 4 weeks.

### Advanced / Aggressive Approach (Acute Injury Support) (2 mL = ~5 mg/mL)

| Week / phase | Daily dose | Each peptide | Units per injection (mL) |
|---|---|---|---|
| Weeks 1–2 (Aggressive Load) | 1 mg (1000 mcg) | 500 mcg BPC + 500 mcg TB-500 | 20 units (0.20 mL) |
| Weeks 3–4 (High Load) | 800 mcg | 400 mcg BPC + 400 mcg TB-500 | 16 units (0.16 mL) |
| Weeks 5–8 (Maintenance) | 600 mcg | 300 mcg BPC + 300 mcg TB-500 | 12 units (0.12 mL) |

Frequency: Once daily, subcutaneously, at a consistent time.

> The blend contains equal amounts of BPC-157 and TB-500, so the total dose is split evenly between both peptides. For acute injuries some references describe a higher initial loading phase; a small case series in joint injuries reported improvement, but no controlled trial exists.

Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

## U-100 Conversion Table

| U-100 units | Volume | Contains | Yield per vial |
|---|---|---|---|
| 2 | 0.02 mL | 100 mcg | 100 injections |
| 5 | 0.05 mL | 250 mcg | 40 injections |
| 10 | 0.10 mL | 500 mcg | 20 injections |
| 20 | 0.20 mL | 1 mg (1000 mcg) | 10 injections |
| 30 | 0.30 mL | 1.5 mg (1500 mcg) | 6 injections |
| 50 | 0.50 mL | 2.5 mg (2500 mcg) | 4 injections |
| 100 | 1.00 mL | 5 mg (5000 mcg) | 2 injections |

## Supplies Needed

**BPC-157 5mg + TB-500 5mg (blend) vials (10 mg each)**
- Standard / Gradual Approach, 12 weeks: Minimum 6 vials (53.2 mg required).
- Standard / Gradual Approach, 24 weeks: Minimum 11 vials (103.6 mg required).
- Advanced / Aggressive Approach (Acute Injury Support), 12 weeks: Minimum 6 vials (58.8 mg required).
- Advanced / Aggressive Approach (Acute Injury Support), 24 weeks: Minimum 11 vials (109.2 mg required).

**U-100 syringes (1 mL)**
- Standard / Gradual Approach, 12 weeks: 84 new syringes for 84 injections.
- Standard / Gradual Approach, 24 weeks: 168 new syringes for 168 injections.
- Advanced / Aggressive Approach (Acute Injury Support), 12 weeks: 84 new syringes for 84 injections.
- Advanced / Aggressive Approach (Acute Injury Support), 24 weeks: 168 new syringes for 168 injections.

**Bacteriostatic water**
- Standard / Gradual Approach, 12 weeks: 12 mL total (2 mL per vial) → 4 × 3 mL vials.
- Standard / Gradual Approach, 24 weeks: 22 mL total (2 mL per vial) → 8 × 3 mL vials.
- Advanced / Aggressive Approach (Acute Injury Support), 12 weeks: 12 mL total (2 mL per vial) → 4 × 3 mL vials.
- Advanced / Aggressive Approach (Acute Injury Support), 24 weeks: 22 mL total (2 mL per vial) → 8 × 3 mL vials.

**Alcohol swabs**
- Standard / Gradual Approach, 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Standard / Gradual Approach, 24 weeks: 336 minimum; one box of 100 does not cover the calculation.
- Advanced / Aggressive Approach (Acute Injury Support), 12 weeks: 168 minimum; one box of 100 does not cover the calculation.
- Advanced / Aggressive Approach (Acute Injury Support), 24 weeks: 336 minimum; one box of 100 does not cover the calculation.

## Storage Instructions

- Lyophilized (unopened): −20 °C for long-term storage; 2–8 °C if used within weeks. Protected from light.
- Reconstituted: 2–8 °C, do not freeze. Use within the documented period (typically up to 4 weeks with bacteriostatic water).
- Handling: do not shake; avoid temperature cycling; label with date and concentration.
- Discard: cloudy solutions, particulates or expired preparations are discarded.

## How This Works

BPC-157 (Body Protection Compound 157): 15-amino-acid pentadecapeptide derived from a protective gastric protein. Stimulates endothelial nitric oxide production, promotes local angiogenesis, and accelerates the healing of tendons, ligaments, and gastrointestinal mucosa. Acts by modulating the nitric oxide system, the VEGFR2 pathway, and expression of genes related to the extracellular matrix. TB-500 (Thymosin Beta-4 fragment): Active analog of Thymosin Beta-4. Its main function is to regulate actin, the protein that organizes the cellular cytoskeleton. This regulation allows cells to migrate to the injury site, form new blood vessels (angiogenesis), and rebuild the damaged extracellular matrix. Sinergia documentada: While BPC-157 accelerates the first repair phase (inflammation control, cellular recruitment), TB-500 covers the secondary phase (sustained angiogenesis, matrix remodeling). Combined, they cover the full arc of the healing process.

## References

1. Modelo preclínico murino
2. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and its role in healing of gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-1632.
3. Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol Med. 2005;11(9):421-429.
4. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780.

---
Source: https://protocolopeptidos.com/en/compuestos/bpc-157-5mg-plus-tb-500-5mg-blend · Important: this guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.